BPC 157

BPC-157 is a synthetic pentadecapeptide (15-amino-acid peptide) derived from a naturally occurring gastric protein fragment. Over the past two decades, it has become one of the most extensively investigated research peptides in regenerative biology, with published studies exploring its interactions with connective tissue physiology, angiogenesis, nitric oxide signalling, growth factor pathways, and cellular repair mechanisms. As a result, BPC-157 is widely used as a laboratory research tool for investigating tissue regeneration and related biological processes in preclinical experimental models.

Researchers in the European Union can buy BPC-157 10 mg from Crystal Peptides as a high-purity research peptide independently tested by accredited laboratories, including Janoshik. Every product batch is accompanied by Certificates of Analysis to verify identity, purity, and analytical quality and determine suitability for research. These certificates can be traced to the testing facility for complete transparency.

BPC-157 has not been authorised as a medicinal product by the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), or any other major medicines regulator. Crystal Peptides supplies BPC-157 exclusively for laboratory research and development and not for human or veterinary use.

Chemical properties and registry information

Research background and published studies

BPC-157 has been investigated extensively in preclinical models of connective tissue biology and regenerative research. Although the peptide's precise molecular target has not been fully established, published studies have examined its interactions with growth factor signalling, angiogenesis, nitric oxide pathways, inflammatory regulation, and cellular migration. The studies sampled here are some of the landmark studies that have shaped current scientific understanding of BPC-157.

Researchers should note that these observations are derived primarily from preclinical investigations and are presented solely to summarise the current scientific literature. They should not be interpreted as evidence of clinical efficacy, therapeutic benefit, or authorised medical use. Crystal Peptides supplies BPC-157 exclusively for laboratory research only in scientific investigation of various applications.

Tendon outgrowth, fibroblast migration, and cell survival (Chang et al., 2011)

Using cultured rat Achilles tendon explants, Chang and colleagues demonstrated that BPC-157 accelerated tendon outgrowth, enhanced fibroblast migration, and improved cell survival under oxidative stress. The peptide did not directly stimulate fibroblast proliferation, suggesting that its effects were mediated through improved cell viability and migration rather than increased cell division. The study also identified activation of the focal adhesion kinase (FAK)-paxillin signalling pathway, providing mechanistic insight into how BPC-157 may influence tendon biology and connective tissue regeneration. [1]

Growth hormone receptor signalling (Chang et al., 2014)

A subsequent study by the same research group demonstrated that BPC-157 increased growth hormone receptor (GHR) expression in tendon fibroblasts at both the mRNA and protein levels. By increasing GHR availability, pretreatment with BPC-157 enhanced growth hormone-induced activation of the downstream JAK2 signalling pathway, providing additional mechanistic evidence for the peptide's interactions with connective tissue physiology. [2]

Musculoskeletal regeneration research (McGuire et al., 2025)

A comprehensive narrative review evaluated the expanding body of preclinical research investigating BPC-157 across tendon, ligament, muscle, bone, and cartilage models. The authors concluded that the available experimental literature demonstrates considerable regenerative potential across multiple musculoskeletal tissues, with the emphasis that the evidence remains predominantly preclinical. Human clinical trials meeting strict regulations are still required before clinical conclusions can be drawn. The review highlights BPC-157 as an important research tool for investigating regenerative biology and connective tissue physiology rather than an established therapeutic agent. [3]

Tissue repair and regenerative biology (Yuan et al., 2026)

A recent review examined the broader scientific literature surrounding BPC-157, including experimental studies investigating connective tissue biology, angiogenesis, inflammatory signalling, and nociceptive pathways. The authors concluded that, while preclinical findings continue to support further laboratory investigation, the peptide's precise molecular targets and potential clinical significance remain incompletely understood. The review reinforces the need for rigorous mechanistic studies and appropriately designed clinical research before any therapeutic conclusions can be drawn. [4]

The observations should not be interpreted as evidence of clinical efficacy, therapeutic benefit, or authorised medical use. BPC-157 peptide is supplied exclusively as a laboratory research reagent for scientific investigation.

BPC-157 mechanism of action

Despite extensive preclinical investigation, the precise molecular target of BPC-157 has not been conclusively identified. Rather than acting through a single receptor, published research suggests that the peptide influences multiple signalling pathways involved in connective tissue physiology, angiogenesis, cellular migration, inflammatory regulation, and tissue homeostasis. Consequently, BPC-157 is generally regarded as a pleiotropic research peptide whose biological activity is likely mediated through interactions with several complementary molecular mechanisms.

Experimental studies have reported that BPC-157 modulates growth factor signalling involved in connective tissue biology, including pathways associated with fibroblast activity and tendon physiology. Research has also demonstrated increased expression of the growth hormone receptor (GHR) in tendon fibroblasts together with enhanced growth hormone-induced activation of the downstream JAK2 signalling pathway, providing mechanistic insight into the peptide's interactions with connective tissue cells.

Another area of active investigation concerns nitric oxide (NO) signalling. Experimental studies suggest that BPC-157 interacts with nitric oxide-dependent pathways involved in vascular homeostasis and endothelial function, while separate investigations have reported effects on angiogenic signalling and the expression of mediators involved in new blood vessel formation. These observations have made BPC-157 a valuable research tool for investigating vascular adaptation and regenerative biology in experimental models.

Additional mechanistic studies have identified activation of focal adhesion kinase (FAK) and paxillin signalling in tendon fibroblasts, pathways that play central roles in cell adhesion, migration, and interactions with the extracellular matrix. Together with reported effects on inflammatory signalling and cellular survival under oxidative stress, these findings support continued investigation into the peptide's role in connective tissue biology and tissue remodelling.

Although these mechanistic observations have significantly expanded scientific understanding of BPC-157, the peptide's primary molecular target and the relative contribution of each signalling pathway remain incompletely characterised. Accordingly, the proposed mechanisms described here should be regarded as areas of ongoing preclinical investigation rather than established explanations of biological activity or evidence of therapeutic efficacy.

BPC-157 research applications

BPC-157 has been investigated across numerous areas of regenerative biology, with particular emphasis on connective tissue physiology, vascular biology, and gastrointestinal research. The applications described below are derived primarily from preclinical investigations and are presented solely to summarise the current scientific literature. They should not be interpreted as evidence of clinical efficacy, therapeutic benefit, or authorised medical use.

Tendon and connective tissue biology

One of the most extensively studied applications of BPC-157 involves connective tissue research. Experimental investigations have examined the peptide in tendon, ligament, muscle, bone, and cartilage models to better understand fibroblast behaviour, extracellular matrix organisation, collagen biology, and the cellular processes involved in tissue remodelling. These studies have made BPC-157 a widely used research tool for investigating connective tissue physiology and regenerative biology. [1]

Angiogenesis and vascular research

BPC-157 has also been investigated in experimental models examining angiogenesis and vascular adaptation. Published studies and recent reviews have explored endothelial cell biology, vascular homeostasis, and the coordinated processes involved in new blood vessel formation during tissue remodelling. These observations continue to support the use of BPC-157 as a research tool for studying vascular responses within broader regenerative models. [2]

Gastrointestinal biology

Because BPC-157 is derived from a naturally occurring gastric protein fragment, early research focused on gastrointestinal tissues and mucosal biology. Subsequent laboratory investigations have expanded this work to include gastric physiology, intestinal biology, epithelial integrity, and inflammatory processes, contributing to a broader understanding of gastrointestinal function in experimental settings. [1,2]

Regenerative biology and experimental models

Beyond individual tissues, BPC-157 is frequently incorporated into experimental models investigating regenerative biology as a whole. Current research explores how the peptide may influence interconnected biological processes including cellular migration, connective tissue organisation, vascular adaptation, inflammatory regulation, and responses to oxidative stress. Collectively, these studies continue to expand scientific understanding of the complex mechanisms involved in tissue regeneration while highlighting the need for further mechanistic and clinical research.

BPC-157 vs TB-500 vs GHK-Cu vs KPV Comparison

BPC-157 is one of several peptides investigated in regenerative biology, each with distinct biological origins and areas of scientific interest. Although these compounds are sometimes discussed together, they differ considerably in their structure, proposed mechanisms of action, and primary areas of laboratory research.

The principal distinction between these peptides lies in the biological processes they are used to investigate. BPC-157 research has focused largely on connective tissue physiology, angiogenesis, growth factor signalling, and gastrointestinal biology. In contrast, TB-500 research, which is derived primarily from studies of thymosin beta-4, centers on cytoskeletal organisation, cellular migration, and tissue remodelling.

GHK-Cu is investigated mainly for extracellular matrix biology, collagen metabolism, and tissue remodelling, while KPV has attracted interest in inflammatory signalling, epithelial biology, and gastrointestinal physiology.

For studies investigating complementary regenerative pathways, some researchers choose multi-peptide formulations that combine peptides with different biological characteristics. For example, the BPC-157 & TB-500 combo (10/10mg blend) combines connective tissue and cytoskeletal research within a single co-lyophilised formulation.

Similarly, the Glow Blend comprises GHK-Cu, BPC-157, and TB-500 for broader investigations involving connective tissue biology, extracellular matrix remodelling, and regenerative processes. These formulations do not represent new molecular entities; rather, they are convenient combinations of individually characterised research peptides for laboratory investigation.

Quality and testing

Crystal Peptides is committed to providing research peptides that meet high standards of analytical quality, consistency, and traceability. Every batch of BPC-157 undergoes HPLC purity analysis and independent third-party verification by accredited laboratories, including Janoshik Analytical. Testing may include peptide identity, peptide content, sterility, endotoxin, and heavy metal screening, with batch-specific Certificates of Analysis available to help researchers verify the analytical characteristics of the exact material supplied.

Because BPC-157 is widely used in regenerative biology research, analytical testing should verify both peptide identity and overall quality. Researchers should look for analytical data including:

• Chromatographic purity by high-performance liquid chromatography (HPLC) to evaluate peptide purity and detect potential impurities or degradation products.
• Molecular identity confirmed by liquid chromatography-mass spectrometry (LC-MS) to verify that the peptide corresponds to the expected molecular mass and amino acid composition.
• Peptide content analysis, confirming that each vial contains the expected quantity of BPC-157.
• Sterility and endotoxin testing, helping ensure the material is suitable for laboratory research where microbiological contamination could compromise experimental results.
• Heavy metal screening, providing additional assurance that residual contaminants from synthesis remain within established laboratory specifications.
• Batch-specific Certificates of Analysis (COAs) documenting the analytical methods used, chromatograms, laboratory results, and independent verification for the exact batch supplied.

Reviewing these analytical results together provides substantially greater confidence than relying on a reported purity percentage alone, helping researchers verify the identity, composition, and analytical quality of the material before incorporating it into experimental work.

For proper handling and storage, BPC-157 is supplied as a lyophilised powder and should be stored sealed, dry, protected from light, and preferably at -20°C or below until required for research.

Reconstitute with bacteriostatic water or sterile water, and afterwards the solution should be refrigerated at 2–8°C, handled using appropriate laboratory procedures, and used according to the laboratory's established stability protocols. Avoid repeated freeze-thaw cycles, prolonged exposure to elevated temperatures, and vigorous agitation, as these practices may contribute to peptide degradation over time.

Regulatory and legal

All products supplied by Crystal Peptides are intended exclusively for research and development purposes. They are provided solely as laboratory research reagents for use by qualified professionals in controlled scientific settings and are not supplied for human or veterinary use.

This product is not a medicinal product, food, food supplement, medical device, cosmetic, or veterinary medicine. The information presented on this page is provided exclusively to summarise the current scientific literature and should not be interpreted as evidence of clinical efficacy, therapeutic benefit, or authorised medical use. Any references to published studies describe experimental research only and have not been evaluated by the European Medicines Agency (EMA) or any other medicines regulator for clinical application.

BPC-157 has not been authorised as a medicinal product by the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), or any other major medicines regulator. Accordingly, Crystal Peptides supplies this compound exclusively for laboratory research and development.

Researchers and purchasers are responsible for ensuring that the acquisition, importation, storage, handling, use, and disposal of research materials comply with all applicable national and local laws and regulations. Because legislation governing research chemicals differs between jurisdictions, customers should confirm the legal requirements applicable within their own country before purchasing or importing laboratory reagents.

Sources and references

• Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-780.
• Chang CH, Tsai WC, Hsu YH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077.
• McGuire FP, Martinez R, Lenz A, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025;18(12):611-619.
• Yuan C, Demers A, Silva-Ortiz V, et al. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. International Journal of Molecular Sciences. 2026;27(6):2876.
• Sikiric P, Seiwerth S, Skrtic A, et al. BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals. 2025;18(10):1450.

Frequently Asked Questions

What is BPC-157?

BPC-157 is a synthetic pentadecapeptide (15-amino-acid peptide) derived from a naturally occurring gastric protein fragment. It has been investigated extensively in preclinical research involving connective tissue physiology, angiogenesis, nitric oxide signalling, and regenerative biology. Although the peptide has attracted considerable scientific interest, it is supplied by Crystal Peptides exclusively as a laboratory research reagent and is not intended for human or veterinary use.

Why is it called BPC-157?

The name BPC stands for Body Protection Compound, reflecting the peptide's origin from a naturally occurring gastric protein that was initially investigated for its biological properties. The designation 157 identifies the specific peptide fragment characterised during its development. Today, BPC-157 refers to the synthetic pentadecapeptide used in laboratory research and described throughout the published scientific literature.

Has BPC-157 been studied in humans?

Most published research involving BPC-157 has been conducted in preclinical models investigating connective tissue biology, angiogenesis, inflammatory signalling, and regenerative processes. While a limited number of clinical observations have been reported, there is currently insufficient high-quality human evidence to establish clinical efficacy or support authorised therapeutic use. Consequently, BPC-157 continues to be investigated primarily as a laboratory research peptide.

Is BPC-157 approved as a medicine?

No. BPC-157 has not been authorised as a medicinal product by the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), or any other major medicines regulator. Crystal Peptides supplies BPC-157 exclusively for research and development purposes and not for human or veterinary use.

How does BPC-157 differ from TB-500?

Although both peptides are widely investigated in regenerative biology, they differ in their biological origin and primary areas of research. BPC-157 is a synthetic pentadecapeptide derived from a naturally occurring gastric protein fragment and has been studied primarily in connective tissue physiology, angiogenesis, nitric oxide signalling, and growth factor pathways. TB-500, by contrast, is a synthetic peptide corresponding to the biologically active region of thymosin beta-4 and is investigated principally for its relationship with cytoskeletal organisation, cell migration, and tissue remodelling. Researchers may investigate the peptides individually or together depending on the objectives of the experimental model.

Does Crystal Peptides provide a Certificate of Analysis (COA)?

Yes. Every batch of BPC-157 supplied by Crystal Peptides is accompanied by a Certificate of Analysis (COA) that can be traced directly to the independent testing laboratory. The COA enables researchers to verify the identity, purity, and analytical characteristics of the exact batch supplied before incorporating it into laboratory research. Crystal Peptides also maintains a dedicated COA library for convenient access to analytical documentation.

How is BPC-157 tested?

Each batch undergoes comprehensive analytical testing before release. Quality control includes HPLC purity analysis to assess chromatographic purity and LC-MS to verify molecular identity. Depending on the batch, additional testing may include peptide content, sterility, endotoxin, and heavy metal screening. Independent third-party verification by accredited laboratories such as Janoshik Analytical provides researchers with confidence in the identity, purity, and analytical quality of the material supplied.

What vial size does Crystal Peptides offer?

Crystal Peptides currently supplies BPC-157 10 mg lyophilised research compound in glass vials, offering superior stability despite temperature fluctuations. Current pricing, product availability, and batch-specific analytical documentation are provided on the product page, allowing researchers to review the relevant information before placing an order.

Where can I buy BPC-157 for research purposes?

Researchers throughout the European Union can buy BPC-157 directly from Crystal Peptides as a high-purity research peptide supplied exclusively for laboratory research. Every batch is independently tested by accredited laboratories and supported by a batch-specific Certificate of Analysis, allowing researchers to verify peptide identity, purity, and analytical quality before experimental use. Crystal Peptides is committed to analytical transparency, reliable fulfilment, and responsive customer support for laboratories and researchers across Europe.

Does Crystal Peptides ship BPC-157 across Europe?

Yes. Crystal Peptides ships BPC-157 throughout Europe using discreet packaging and tracked delivery services. Orders are typically dispatched promptly, with delivery times varying by destination country, and express shipping is available for many European locations. Researchers can review shipping options, estimated delivery times, accepted payment methods, and country-specific ordering information before placing an order.